Fusion protein and use thereof
US12304967B2 · kind B2 · utility
0Cited by
5References
16Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Nov 13, 2019 |
| Grant date | May 20, 2025 |
| Priority date | — |
| Expiry date | Sep 17, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/33
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided is a fusion protein, comprising a first binding domain that specifically binds a tumor-associated antigen, and a second binding domain that specifically binds a CD47 protein, wherein the second binding domain comprises a mutant of a human SIRPα variant 1. Also provided are an immunoconjugate, nucleic acid molecules, vectors, compositions, and cells related to the fusion protein and preparation methods therefor, and the uses thereof in the preparation of medicaments.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.